MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3899/jrheum.2024-0536

Медицинская библиотека · The Journal of rheumatology · 2025

Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial.

Consolaro Alessandro, Ruperto Nicolino, Lovell Daniel J, Synoverska Olga, Abud-Mendoza Carlos, Spindler Alberto, Vyzhga Yulia, Alexeeva Ekaterina, Chaitow Jeffrey, Chiraseveenuprapund Peter, Lazariciu Irina, Stockert Lori, Cadatal Mary Jane, Diehl Annette, Brunner Hermine I, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

СтатьяКлиническое исследование III фазыРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVE

To evaluate rates of clinically inactive disease (CID) and remission in patients with juvenile idiopathic arthritis (JIA) receiving tofacitinib using the 2021 Juvenile Arthritis Disease Activity Score (JADAS) thresholds and American College of Rheumatology (ACR) criteria.

METHODS

This post hoc analysis included patients with active JIA (polyarticular-course JIA, psoriatic arthritis, or enthesitis-related arthritis) enrolled in a phase III randomized withdrawal study of tofacitinib. In part 1 (weeks 0-18), patients received open-label tofacitinib. In part 2 (weeks 18-44), patients who achieved ACR improvement ≥ 30% were randomized to tofacitinib or placebo for 26 weeks or until JIA flare. Disease activity was assessed using the JADAS in 10 joints (JADAS10) based on C-reactive protein, with interpretation according to 2021 polyarthritis thresholds. JADAS10 remission was defined as ≥ 24 continuous weeks of JADAS10 CID (JADAS10-CID). ACR CID (ACR-CID) and ACR clinical remission were also assessed.

RESULTS

Of 225 patients with JIA in part 1, 173 (76.9%) were randomized in part 2 to continue tofacitinib or switch to placebo. Rates of JADAS10-CID and ACR-CID increased throughout part 1 to 30.5% and 15.8% (week 18), respectively. In part 2, these were sustained with tofacitinib (week 44: 35.2% [JADAS10-CID], 25% [ACR-CID]) and decreased when patients switched to placebo (week 44: 25.9% [JADAS10-CID], 15.3% [ACR-CID]). A small proportion of patients achieved JADAS10 remission at week 44 (tofacitinib: 14.8%; placebo: 7.1%).

CONCLUSION

In patients with JIA receiving tofacitinib, JADAS10-CID and ACR-CID rates improved rapidly and were sustained over time, and a small proportion of patients achieved JADAS10 remission. Inactive disease is a feasible treatment target in patients receiving tofacitinib. (ClinicalTrials.gov: NCT02592434).

Для цитирования: Consolaro Alessandro, Ruperto Nicolino, Lovell Daniel J, Synoverska Olga, Abud-Mendoza Carlos, Spindler Alberto, Vyzhga Yulia, Alexeeva Ekaterina, Chaitow Jeffrey, Chiraseveenuprapund Peter, Lazariciu Irina, Stockert Lori, Cadatal Mary Jane, Diehl Annette, Brunner Hermine I, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial.. The Journal of rheumatology. 2025. DOI: 10.3899/jrheum.2024-0536.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.